Similarly, rosuvastatin monotherapy had specificity to T-cell lymphomas harboring a p53 R248Q DNA contact mutation but not in tumor cells expressing an R172H p53 conformational mutation [160]. The gene discussed is TP53; the disease is T-cell non-Hodgkin lymphoma.